Precision oncology trials based on cancer biomarkers have the potential to improve outcomes by guiding the optimal choice of therapies for patients. For this to be truly achieved, computational methods such as virtual molecular tumor boards, dynamic precision medicine and digital twins are needed to support cohort selection and trial enrollment at scale.
References
Prasad, V., Fojo, T. & Brada, M. Lancet Oncol. 17, e81–e86 (2016).
Esserman, L.J. et al. J. Clin. Oncol. https://doi.org/10.1200/jco.2009.27.18_suppl.lba515 (2009).
McNeil, C. J. Natl. Cancer Inst. 107, djv193 (2015).
Liu, J. et al. Cell 173, 400–416.e11 (2018).
Edwards, N. J. et al. J. Proteome Res. 14, 2707–2713 (2015).
Rozenblatt-Rosen, O. et al. Cell 181, 236–249 (2020).
Rolfo, C. et al. ESMO Open 3, e000398 (2018).
Rao, S. et al. JCO Clin. Cancer Inform. 4, 602–613 (2020).
Pishvaian, M. J. et al. JAMIA Open 2, 505–515 (2019).
Lamping, M. et al. Eur. J. Cancer 127, 41–51 (2020).
Beckman, R. A., Schemmann, G. S. & Yeang, C.-H. Proc. Natl Acad. Sci. USA 109, 14586–14591 (2012).
Alber, M. et al. NPJ Digit. Med. 2, 115 (2019).
Rasheed, A., San, O. & Kvamsdal, T. arXiv https://arxiv.org/abs/1910.01719 (2019).
Kim, E., Rebecca, V. W., Smalley, K. S. M. & Anderson, A. R. A. Eur. J. Cancer 67, 213–222 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.R.B. reports personal fees (consulting fee) from Perthera.
Rights and permissions
About this article
Cite this article
Madhavan, S., Beckman, R.A., McCoy, M.D. et al. Envisioning the future of precision oncology trials. Nat Cancer 2, 9–11 (2021). https://doi.org/10.1038/s43018-020-00163-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-020-00163-8
- Springer Nature America, Inc.
This article is cited by
-
A federated learning system for precision oncology in Europe: DigiONE
Nature Medicine (2024)
-
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information
Experimental Hematology & Oncology (2022)
-
How artificial intelligence might disrupt diagnostics in hematology in the near future
Oncogene (2021)